228 related articles for article (PubMed ID: 34524860)
1. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
Lightcap ES; Yu P; Grossman S; Song K; Khattar M; Xega K; He X; Gavin JM; Imaichi H; Garnsey JJ; Koenig E; Zhang H; Lu Z; Shah P; Fu Y; Milhollen MA; Hatton BA; Riceberg J; Shinde V; Li C; Minissale J; Yang X; England D; Klinghoffer RA; Langston S; Galvin K; Shapiro G; Pulukuri SM; Fuchs SY; Huszar D
Sci Transl Med; 2021 Sep; 13(611):eaba7791. PubMed ID: 34524860
[TBL] [Abstract][Full Text] [Related]
2. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Nakamura A; Grossman S; Song K; Xega K; Zhang Y; Cvet D; Berger A; Shapiro G; Huszar D
Blood; 2022 May; 139(18):2770-2781. PubMed ID: 35226739
[TBL] [Abstract][Full Text] [Related]
3. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
4. T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Lam V; Roleder C; Liu T; Bruss N; Best S; Wang X; Phillips T; Shouse G; Berger AJ; Alinari L; Wang L; Siddiqi T; Pennock ND; Danilov AV
Mol Cancer Ther; 2023 Sep; 22(9):1040-1051. PubMed ID: 37420267
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
Gabellier L; De Toledo M; Chakraborty M; Akl D; Hallal R; Aqrouq M; Buonocore G; Recasens-Zorzo C; Cartron G; Delort A; Piechaczyk M; Tempé D; Bossis G
Haematologica; 2024 Jan; 109(1):98-114. PubMed ID: 37608777
[TBL] [Abstract][Full Text] [Related]
6. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
[TBL] [Abstract][Full Text] [Related]
7. Targeting SUMOylation in cancer.
Du L; Liu W; Rosen ST
Curr Opin Oncol; 2021 Sep; 33(5):520-525. PubMed ID: 34280172
[TBL] [Abstract][Full Text] [Related]
8. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.
Kim HS; Kim BR; Dao TTP; Kim JM; Kim YJ; Son H; Jo S; Kim D; Kim J; Suh YJ; Kim HJ; Cho BS; Park S
Blood Adv; 2023 Jul; 7(13):3155-3168. PubMed ID: 36809797
[TBL] [Abstract][Full Text] [Related]
9. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
10. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
Langston SP; Grossman S; England D; Afroze R; Bence N; Bowman D; Bump N; Chau R; Chuang BC; Claiborne C; Cohen L; Connolly K; Duffey M; Durvasula N; Freeze S; Gallery M; Galvin K; Gaulin J; Gershman R; Greenspan P; Grieves J; Guo J; Gulavita N; Hailu S; He X; Hoar K; Hu Y; Hu Z; Ito M; Kim MS; Lane SW; Lok D; Lublinsky A; Mallender W; McIntyre C; Minissale J; Mizutani H; Mizutani M; Molchinova N; Ono K; Patil A; Qian M; Riceberg J; Shindi V; Sintchak MD; Song K; Soucy T; Wang Y; Xu H; Yang X; Zawadzka A; Zhang J; Pulukuri SM
J Med Chem; 2021 Mar; 64(5):2501-2520. PubMed ID: 33631934
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
[TBL] [Abstract][Full Text] [Related]
12. A Potent
Zhang KJ; Yin XF; Yang YQ; Li HL; Xu YN; Chen LY; Liu XJ; Yuan SJ; Fang XL; Xiao J; Wu S; Xu HN; Chu L; Katlinski KV; Katlinskaya YV; Guo RB; Wei GW; Wang DC; Liu XY; Fuchs SY
Clin Cancer Res; 2017 Apr; 23(8):2038-2049. PubMed ID: 27683179
[No Abstract] [Full Text] [Related]
13. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the regulatory roles of the SUMO.
Hwang KW; Won TJ; Kim H; Chun HJ; Chun T; Park Y
Diabetes Metab Res Rev; 2011 Nov; 27(8):854-61. PubMed ID: 22069273
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
16. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G; Kodumudi K; Snyder C; Grover P; Zhang H; Greene MI; Basu A; Gallen C; Wiener D; Costa RLB; Han HS; Koski G; Czerniecki BJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710296
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
19. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
[TBL] [Abstract][Full Text] [Related]
20.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
